Brenipatide for Depression

(RENEW-MDD- 2 Trial)

This trial tests a new treatment called brenipatide, a potential antidepressant, to determine if it can delay the return of depression symptoms when combined with standard care. Participants will receive one of three doses of brenipatide or a placebo, alongside their usual treatment. It suits individuals with stable treatment for major depressive disorder who can manage self-injections and track their treatment. As a Phase 3 trial, this study represents the final step before FDA approval, providing participants an opportunity to contribute to the potential availability of a new treatment option.

No, you do not have to stop taking your current medications. The trial requires that you are on stable standard of care medication for major depressive disorder.

Research has shown that brenipatide has undergone testing in several studies to assess its safety in people. In trials for conditions like bipolar disorder and asthma, participants generally tolerated brenipatide well. Common side effects were mild, such as headaches or nausea, and serious side effects were rare.

For instance, studies involving people with asthma found that brenipatide was safe when used alongside standard treatments. Another study with individuals who had quit smoking also demonstrated that brenipatide was safe compared to a placebo.

Brenipatide is unique because it targets depression differently than typical antidepressants like SSRIs or SNRIs, which mainly focus on serotonin or norepinephrine. This treatment is administered subcutaneously, which can offer a more consistent delivery compared to oral medications. Researchers are particularly excited because Brenipatide could potentially provide faster relief from depressive symptoms, which is a significant improvement over current options that often take weeks to show effectiveness.

Research has shown that depression ranks among the most treatable mental health conditions. Studies indicate that 70% to 90% of people with depression respond well to treatment. This trial examines Brenipatide as a new option to help prevent the return of major depressive symptoms. Participants will receive varying doses of Brenipatide or a placebo, alongside standard care, to test its potential benefits. The goal is to discover more effective ways to manage depression.⁶⁷⁸⁹¹⁰